EDGC eyes global market debut of its early cancer test solution next year
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Songdo, Incheon-based EDGC is conducting clinical trials in Korea to evaluate its liquid biopsy solution for the analysis of circulating tumor DNA (ctDNA) as a method of noninvasively characterizing tumors and tumor genome from a blood sample.
Shin said his company along with Grail now under U.S. Illumina, the global leader in DNA sequencing, is ahead in the global cancer test race. The two will likely draw attention at the international conference to be held in February 2022 in California.
In September 2020, San Diego-based Illumina announced its acquisition of Grail, a startup that spun out from Illumina six years ago, for cash and stock consideration of $8 billion.
EDGC¡¯s liquid biopsy technology is part of super-precision medicine to detect abnormal forms of circulating cell-free DNA (cfDNA) that originate from cancer cells (ctDNA), a precursor to developing cancer. If there is any ctDNA, it exists in an extremely small amount among cfDNA in blood. This technology is expected to bring about a major innovation in the field of cancer diagnosis.
EDGC is the only Asian company that participated in an international mega project designed to analyze and standardize genome data of 10 million people in 2016, according to Shin.
Early-stage cancer is difficult to be detected because the amount of ctDNA is too low. To tackle this problem, the company developed a technology that extracts methylation patterns specific to cancer genomes with next-generation sequencing (NGS) and analyzes them with artificial intelligence (AI) algorithms, Shin explained.
With this technology, EDGC can analyze more than tens of thousands of methylation markers and trace amounts of ctDNA with high sensitivity.
If OncoCatch is covered by a national health checkup program, individuals will be able to know whether they have cancer much earlier than now by simply collecting blood, Shin said, adding this service is already offered in some general hospitals in Hong Kong and Ukraine.
The current detection rate for breast cancer, colorectal cancer, and lung cancer through OncoCatch has surpassed 90 percent in sensitivity and specificity, and EDGC is working to raise detection accuracy for gastric cancer to over 90 percent in stage 1, Shin said.
[¨Ï Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Meta’s metaverse chief sees explosive growth of metaverse in two years - Pulse by Maeil Business News Korea
- CJ CheilJedang to field chicken, kimchi, red pepper sause, rice, gim and mandu as global players - Pulse by Maeil Business News
- Tourists from 63 countries now exempt from quarantine rules - Pulse by Maeil Business News Korea
- Prosperity tax to support government initiatives in trying times, say tax experts - Pulse by Maeil Business News Korea
- EDGC eyes global market debut of its early cancer test solution next year - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- 40평 대신 조금 더 보태 50~60평 산다
- “신뢰 잃었다”…‘성범죄’ 태일, NCT 이어 SM서도 퇴출[공식입장] - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이